NMTC achieved a major operational turnaround with 164% revenue growth, successful product commercialization including the December 2025 launch of OneRF TN Ablation System, and a dramatic improvement in net losses from $12.3M to $3.6M.
The company has successfully transitioned from a development-stage entity to an active commercialization phase, evidenced by the market release of new products and a distribution partnership with Zimmer. The substantial increase in outstanding shares (from 30.8M to 50.4M) suggests recent equity financing that funded this growth phase, positioning the company for continued expansion.
NMTC delivered exceptional financial improvement across all key metrics, with revenue jumping 164% to $9.1M and gross profit surging 376% to $5.1M, indicating strong pricing power and operational leverage. The balance sheet strengthened significantly with cash increasing 350% to $6.6M and stockholders' equity growing 760% to $7.1M, while net losses improved dramatically by 71% despite the growth investments. Operating cash flow deficit narrowed substantially from $11.0M to $2.8M, signaling the company is approaching cash flow breakeven as commercialization efforts gain traction.
Equity base grew 760.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Receivables surged 616.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Cash position surged 350% — strong cash generation or capital raise providing significant financial cushion.
Strong top-line growth of 163.5% — accelerating demand or successful expansion into new markets.
Current assets grew 120.8% — improving short-term liquidity or inventory/receivables build.
Asset base grew 100.9% — expansion through organic growth, acquisitions, or capital deployment.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Operating cash flow surged 74.2% — exceptional cash generation, highest quality earnings signal.
Net income grew 70.7% — bottom-line growth signals improving overall business health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →